May 6 (Reuters) -

The U.S. Centers for Disease Control and Prevention has

accepted its advisory panel's recommendations on vaccines for

chikungunya, a virus transmitted by mosquitoes.

The recommendations were approved on May 13, 2025, and

are now the official recommendations of the CDC.

The final recommendations will assist physicians in

choosing appropriate vaccines for patients and will also guide

insurance coverage policies in the U.S.

The health agency is also expected to decide on

recommendations for vaccines against respiratory syncytial virus

(RSV) and meningococcal disease, a bacterial infection.

However, details regarding the approval status of the

RSV and meningococcal vaccine recommendations are currently not

available on the CDC's website.

Both Bavarian Nordic ( BVNKF ) and Valneva make

vaccines for chikungunya.